Structure-activity relationship of trans-resveratrol and its analogues

Neoplasma

Volumn 52, Issue 6, 2005, Pages 450-455

  Ovesna Z ^a   Horvathova Kozics K ^a  

^a INSTITUTE OF CHEMISTRY   (Slovakia)

Author keywords

Antioxidant activity; Chemopreventive activity; Piceatannol; Structure activity relationship; Trans resveratrol

Indexed keywords

3' HYDROXYPTEROSTILBENE; HYDROXYL GROUP; PHYTOALEXIN; PICEATANNOL; PTEROSTILBENE; RESVERATROL; RESVERATROL DERIVATIVE; STILBENE; STILBENE DERIVATIVE; UNCLASSIFIED DRUG;

CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PREVENTION; CHEMICAL BINDING; CHEMOPROPHYLAXIS; DRUG ACTIVITY; GRAPE; HUMAN; HYDROGEN BOND; SHORT SURVEY; STEREOISOMERISM; STRUCTURE ACTIVITY RELATION;

EID: 29144511498     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (48)

1. BAVARESCO L. Role of viticultural factors on stilbene concentrations of grapes and wine. Drugs Exp Clin Res 2003; 29: 181-187.
2. BOLTON JL. Quinoids, quinoid radicals, and phenoxyl radicals formed from estrogens and antiestrogens. Toxicology 2002; 177: 55-65.
3. BOWERS JL, TYULMENKOV W, JERNIGAN SC, KLINGE CM. Resveratrol acts as a mixed agonist/antagonist for estrogen receptors alpha and beta. Endocrinology 2000; 141: 3657-3667.
4. BURNS J, YOKOTA T, ASHIHARA H, LEAN ME, CROZIER A. Plant foods and herbal sources of resveratrol. J Agric Food Chem 2002; 50: 3337-3340.
5. CAI YJ, FANG JG, MA LP, YANG L, LIU ZL. Inhibition of free radical-induced peroxidation of rat liver microsomes by resveratrol and its analogues. Biochim Biophys Acta 2003; 1637: 31-38.
6. CAI YJ, WEI QY, FANG JG, YANG L, LIU ZL et al. The 3,4-dihydroxyl groups are important for trans-resveratrol analogs to exhibit enhanced antioxidant and apoptotic activities. Anticancer Res 2004; 24: 999-1002.
7. CARUSO F, TANSKI J, VILLEGAS-ESTRADA A, ROSSI M. Structural basis for antioxidant activity of trans-resveratrol: ab initio calculations and crystal and molecular structure. J Agric Food Chem 2004; 52: 7279-7285.
8. CHUNG MI, TENG CM, CHENG KL, KO FN, LIN CN. An antiplatelet principle of Veratrum formosanum. Planta Med 1992; 58: 274-276.
9. DAMIANAKI A, BAKOGEORGOU E, KAMPA M, NOTAS G, HATZOGLOU A et al. Potent inhibitory action of red wine polyphenols on human breast cancer cells. J Cell Biochem 2000; 78: 429-441.
10. DONG Z. Molecular mechanism of the chemopreventive effect of resveratrol. Mutat Res 2003; 523-524: 145-150.
11. EMBADADUL HM, ASANUMA M, HIGASHI Y, MIYAZAKI I, TANAKA K et al. Apoptosis-inducing neurotoxicity of dopamine and its metabolites via reactive quinone generation in neuroblastoma cells. Biochim Biophys Acta 2003; 1619: 39-52.
12. FANG JG, LU M, CHEN ZH, ZHU HH, LI Y et al. Antioxidant effects of resveratrol and its analogues against the free-radical-induced peroxidation of linoleic acid in micelles. Chem Eur J 2002; 8: 4191-4198.
13. FAUCONNEAU B, WAFFO-TEGUO P, HUGUET F, BARRIER L, DECENDIT A et al. Comparative study of radical scavenger and antioxidant properties of phenolic compounds from Vitis vinifera cell cultures using in vitro tests. Life Sci 1997; 61: 2103-2110.
14. FONTECAVE M. Ribonucleotide reductases and radical reactions. Cell Mol Life Sci 1998; 54: 684-695.
15. FOTI M, RUBERTO G. Kinetic solvent effects on phenolic antioxidants determined by spectrophotometric measurements. J Agric Food Chem 2001; 49: 342-348.
16. FREMONT L. Biological effects of resveratrol. Life Sci 2000; 66: 663-673.
17. GAUTAM SC, XU YX, DUMAGUIN M, JANAKIRAMAN N, CHAPMAN RA. Resveratrol selectively inhibits leukemia cells: a prospective agent for ex vivo bone marrow purging. Bone Marrow Transplant 2000; 25: 639-645.
18. GEHM BD, MCANDREWS JM, CHIEN PY, JAMESON JL. Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor. Proc Natl Acad Sci USA 1997; 94: 14138-14143.
19. GOLDBERG DM, YAN J, SOLEAS GJ. Absorption of three wine-related polyphenols in three different matrices by healthy subjects. Clin Biochem 2003; 36: 79-87.
20. HUNG LM, CHEN JK, LEE RS, LIANG HC, SU MJ. Beneficial effects of astringinin, a resveratrol analogue, on the ischemia and reperfusion damage in rat heart. Free Radic Biol Med 2001; 30: 877-883.
21. HUNG LM, SU MJ, CHU WK, CHIAO CW, CHAN WF et al. The protective effect of resveratrols on ischaemia-reperfusion injuries of rat hearts is correlated with antioxidant efficacy. Br J Pharmacol 2002; 135: 1627-1633.
22. JANG M, CAI L, UDEANI GO, SLOWING KV, THOMAS CF et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997; 275: 218-220.
23. KIMURA Y, OKUDA H, ARICHI S. Effects of stilbenes on arachidonate metabolism in leukocytes. Biochim Biophys Acta 1985; 834: 275-278.
24. LE CORRE L, CHALABI N, DELORT L, BIGNON YJ, BERNARD-GALLON DJ. Resveratrol and breast cancer chemoprevention: molecular mechanisms. Mol Nutr Food Res 2005; 49: 462-471.
25. MATSUOKA A, FURUTA A, OZAKI M, FUKUHARA K, MIYATA N. Resveratrol, a naturally occurring polyphenol, induces sister chromatid exchanges in a Chinese hamster lung (CHL) cell line. Mutat Res 2001; 494: 107-113.
26. MATSUOKA A, TAKESHITA K, FURUTA A, OZAKI M, FUKUHARA K et al. The 4′-hydroxy group is responsible for the in vitro cytogenetic activity of resveratrol. Mutat Res 2002; 521: 29-35.
27. MITCHELL SH, ZHU W, YOUNG CY. Resveratrol inhibits the expression and function of the androgen receptor in LNCP prostate cancer cells. Cancer Res 1999; 59: 5892-5895.
28. MURIAS M, HANDLER N, ERKER T, PLEBAN K, ECKER G et al. Resveratrol analogues as selective cyclooxygenase-2 inhibitors: synthesis and structure-activity relationship. Bioorg Med Chem 2004; 12: 5571-5578.
29. MURIAS M, JÄGER W, HANDLER N, ERKER T, HORVATH Z et al. Antioxidant, prooxidant and cytotoxic activity of hydroxylated resveratrol analogues: structure-activity relationship. Biochem Pharmacol 2005; 69: 903-912.
30. OHGUCHI K, TANAKA T, ITO T, IINUMA M, MATSUMOTO K et al. Inhibitory effects of resveratrol derivatives from Dipterocarpaceae plants on tyrosinase activity. Biosci Biotechnol Biochem 2003; 67: 1587-1589.
31. OVESNÁ Z, VACHÁLKOVÁ A, HORVÁTHOVÁ K, TÓTHOVÁ D. Pentacyclic triterpenoic acids: new chemoprotective compounds. Neoplasma 2004; 51: 327-333.
32. OVESNÁ Z, VACHÁLKOVÁ A, HORVÁTHOVÁ K. Taraxasterol and β-sitosterol: new naturally compounds with chemoprotective/chemopreventive effects. Neoplasma 2004; 51: 407-414.
33. PACE-ASCIAK CR, HAHN S, DIAMANDIS EP, SOLEAS G, GOLDBERG DM. The red wine phenolics trans-resveratrol and quercetin block human platelet aggregation and eicosanoid synthesis: implications for protection against coronary heart disease. Clin Chim Acta 1995; 235: 207-219.
34. POTTER GA, PATTERSON LH, WANOGHO E, PERRY PJ, BUTLER PC et al. The cancer preventive agent resveratrol is converted to the anticancer agent piceatannol by the cytochrome P450 enzyme Cyp1B1. Br J Cancer 2002; 86: 774-778.
35. POZO-GUISADO E, ALVAREZ-BARRIENTOS A, MULERO-NAVARRO S, SANTIAGO-JOSEFAT B, FERNANDEZ-SALGUERO PM. The antiproliferative activity of resveratrol results in apoptosis in MCF-7 but not in MDA-MB-231 human breast cancer cells: cell-specific alteration of the cell cycle. Biochem Pharmacol 2002; 64: 1375-1386.
36. RAGIONE FD, CUCCIOLLA V, BORRIELLO A, PIETRA VD, RACIOPPI L et al. Resveratrol arrests the cell division cycle at S/G2 phase transition. Biochem Biophys Res Commun 1998; 250: 53-58.
37. ROBERTI M, PIZZIRANI D, SIMONI D, RONDANIN R, BARUCHELLO R et al. Synthesis and biological evaluation of resveratrol and analogues as apoptosis-inducing agents. J Med Chem 2003; 46: 3546-3554.
38. SCHNEIDER Y, VINCENT F, DURANTON B, BADOLO L, GOSSE F et al. Anti-proliferative effect of resveratrol, a natural component of grapes and wine, on human colonic cancer cells. Cancer Lett 2000; 158: 85-91.
39. SCHUBERT R, FISCHER R, HAIN R, SCHREIER PH, BAHNWEG G et al. An ozone responsive region of the grape-wine resveratrol synthetase promoter differs from the basal pathogen-responsive sequence. Plant Mol Biol 1997; 34: 417-426.
40. SOLEAS GJ, DIAMANDIS EP, GOLDBERG DM. Resveratrol: a molecule whose time has come? And gone? Clin Biochem 1997; 30: 91-113.
41. STIVALA LA, SAVIO M, CARAFOLI F, PERUCCA P, BIANCI L et al. Specific structural determinants are responsible for the antioxidant activity and the cell cycle effects of resveratrol. J Biol Chem 2001; 276: 22586-22594.
42. STOJANOVIC S, SPRINZ H, BREDE O. Efficiency and mechanism of the antioxidant action of trans-resveratrol and its analogues in the radical liposome oxidation. Arch Biochem Biophys 2001; 391: 79-89.
43. TOLOMEO M, GRIMAUDO S, DI CRISTINA A, ROBERTI M, PIZZIRANI D et al. Pterostilbene and 3′-hydroxypterostilbene are effective apoptosis-inducing agents in MDR and BCR-ABL-expressing leukemia cells. Int J Biochem Cell Biol 2005; 37: 1709-1726.
44. WENZEL E, SOMOZA V. Metabolism and bioavailability of trans-resveratrol. Mol Nutr Food Res 2005; 49: 472-481.
45. WOLTER F, CLAUSNITZER A, AKOGLU B, STEIN J. Piceatannol, a natural analog of resveratrol, inhibits progression through the S phase of the cell cycle in colorectal cancer cell lines. J Nutr 2002; 132: 298-302.
46. WRIGHT JS, JOHNSON ER, DILABIO GA. Predicting the activity of phenolic antioxidants: theoretical method, analysis of substituent effects, and application to major families of antioxidants. J Am Chem Soc 2001; 123: 1173-1183.
47. YU C, SHIN YG, CHOW A, LI Y, KOSMEDER JW et al. Human, rat, and mouse metabolism of resveratrol. Pharm Res 2002; 19: 1907-1914.
48. ZHOU HB, YAN Y, SUN YN, ZHU JR. Resveratrol induces apoptosis in human esophageal carcinoma cells. World J Gastroenterol 2003; 9: 408-411.